AIDS Therapies (Clinical Trials)

'Survivor Treatment Selection Bias' Encumbers AIDS Studies

Published in AIDS Weekly, June 17th, 1996

"Survivor treatment selection bias is an important potential limitation of the analysis of observational treatment studies," suggested researchers at Johns Hopkins, Baltimore, Maryland.

Although the "gold standard" of treatment evaluation is the randomized, clinical trial, randomized clinical trials are not always possible for ethical and economic reasons. In an issue of the Annals of Internal Medicine (Ann Intern Med 1996;124:999-1005), Dr. Marshall J. Glesby explained the potential hazards of the bias associated with observational treatment studies, which he said are often overlooked.

Survivor treatment selection bias can erroneously lead...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry